Sagar Cements Ltd (502090 )- Growing in Line with Industry

Sagar Cements Ltd (502090 ) closes   at ₹208.06  with  a   Gain  of   +2.60 %   on    28-July-2023  with formation of  a    bullish engulfing candle  on Daily  Price Chart.

About the Company : Sagar Cements Ltd is an India-based company, which is engaged in the manufacture and sale of cement. It is also focused on the generation of power for sale and captive consumption

Sector Update :  Positive

Refinitiv  Average Score : 5/ 10

Financials : Sagar Cements Ltd  has posted Net Sales / Revenue   of ₹2229.50 Cr & Net Loss of   - ₹88.60 Cr in FY2023 and expected to post Net Sales / Revenue   of ₹2743.70 Cr  & Net Profit of ₹12.20  Cr in FY2024, Net Sales / Revenue   of ₹3345.60 Cr  & Net Profit of ₹120.20  in FY2025 and Net Sales / Revenue   of ₹353971.00 Cr  & Net Profit of ₹9029.20 Cr in FY20.26.

Valuations  : The Company is now Trading at X0.54 of its  valuations of  FY2023 (Last 4 Quarters ) earnings with ~46% discount  ;  at X16.02 of its FY2024 earnings with ~1502%  Premium ; at X1.63 of its FY2025 earnings with ~63%  Premium.

Company will reduce its total debt of ₹1475.70 Cr in FY 2023 to ₹1235.60 by FY 2025 with improving the Debt/Equity Ration to 0.6(FY2025) from 0.70(FY2023)

Book Value Per Share  will  improve from ₹129.20 in FY2023 to ₹138.40 in FY2025  and RoE from -5.90%  to 6.80% during the same period and EPS from -6.8 to 9.20 .

Early Trend : Demand is healthy and housing and infra demand is strong. Management expects 8-10% industry growth in the market it services.(Lastest Con Call )

MF/FII : 19.59% HoldingMargin of Safety (1Yr Bond Yield: Value>1 ) is now  0.2  which  will increase  in FY2024 as soon as it comes out from Looses.The  Equity Value Per Share ( Enterprise Value Method ) is  ₹192.70If We factor its FY2025 earnings/valuations, relative to current valuations,  its Price arrives at ₹693.46

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source | NSE Website | Screener.In  | Capital Line | Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D

 

Indian Railway Finance Corporation Ltd (543257 )- यात्रीगण कृपया ध्यान दें

Indian Railway Finance Corporation Ltd  (543257 ) closes   at ₹35.06  with  a   Gain  of   +0.70%%   on    28-July-2023  with formation of  a   long-legged doji candle  on Daily  Price Chart.

About the Company : Incorporated in 1986, Indian Railway Finance Corporation borrows funds from the financial markets to finance the acquisition / creation of assets which are then leased out to the Indian Railways as finance lease^.

Sector Update :  Positive

Refinitiv  Average Score : 06/ 10

Financials : Indian Railway Finance Corporation Ltd  has posted Net Sales / Revenue   of ₹23892 Cr & Net Profit of   ₹6314.30 Cr in FY2023 and expected to post Net Sales / Revenue   of ₹272369.00 Cr  & Net Profit of ₹6937.80 Cr in FY2024, Net Sales / Revenue   of ₹310500.00 Cr  & Net Profit of ₹7914.80Cr in FY2025 and Net Sales / Revenue   of ₹353971.00 Cr  & Net Profit of ₹9029.20 Cr in FY2026.

Valuations  : The Company is now Trading at X0.70 of its  valuations of  FY2023 (Last 4 Quarters ) earnings with ~30% discount  ;  at X0.47 of its FY2024 earnings with ~53%  Discount ; at X0.41 of its FY2025 earnings with ~59%  Premium  and at X0.36 of its FY2026 earnings with ~64%  Discount .

 Book Value Per Share  will  improve from ₹34.80 in FY2023 to ₹50.70 in FY2026  and RoE(change) from 13.9%% to 13.60% during the same period.

Early Trend : The government, in the forthcoming budget, is also likely to propose laying 100,000 km of new railway tracks over the next 25 years. And also, complete the electrification of the entire rail network. IRFC's cumulative funding to rail sector has crossed Rs.5 trillion by March 2022. The funds are utilized for acquiring rolling stock assets and also building up infrastructure, of Indian Railways.

MF/FII : Baroda BNP Paribas Flexi Cap Fund Regular Growth was the highest buyer of 3,000,000 shares in Jun 2023 constituting 0.02% of the paid up equity of the company

Margin of Safety (1Yr Bond Yield: Value>1 ) is now  1.6 which  makes is attractive.The  Equity Value Per Share ( Enterprise Value Method ) is  ₹34.60

If We factor its FY2026 earnings/valuations, its Price arrives at ₹96.80

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source | NSE Website | Screener.In  | Capital Line | Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D

 

Krishna Institute of Medical Sciences Ltd (543308)-Entry into Nagpur market

Krishna Institute of Medical Sciences Ltd (543308) closes   at ₹1238.35 with  a   Loss of   -3.00%   on    12-September-2022  with formation of  a  Long Red   Candle    on Daily  Price Chart.

About the Company : Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1

Sector Update :  Positive

Refinitiv  Average Score : 09/ 10

Financials : Krishna Institute of Medical Sciences Ltd  has posted Net Sales / Revenue   of ₹1650.80 Cr & Net Profit of   ₹332.70 Cr in FY2022 and expected to post Net Sales / Revenue   of ₹2213.80 Cr  & Net Profit of ₹334.60 Cr in FY2023, Net Sales / Revenue   of ₹2405.30 Cr  & Net Profit of ₹392.60 Cr in FY2024 and Net Sales / Revenue   of ₹2817.30 Cr  & Net Profit of ₹437.60 Cr in FY2025.

Valuations  : The Company is now Trading at X2.90 of its  valuations of  FY2022 (Last 4 Quarters ) earnings with ~290% premium ;  at X2.13 of its FY2023 earnings with ~213%  Premium and at X1.82 of its FY2024 earnings with ~182%  Premium .

EPS  will  improve from 41.60 in FY2022 to 54.70  in FY2025  and RoE from 29.60% to 20.40% during the same period.

Early Trend : Entring into Nagpur market.

MF/FII : ICICI PRUDENTIAL MUTUAL FUND A/C - ICICI PRUDENTIAL SMALLCAP FUND has bought it on 12.09.2022

Margin of Safety (1Yr Bond Yield: Value>1 ) is now  0.40 which  makes is attractive after 60% decline .The  Equity Value Per Share ( Enterprise Value Method ) is  ₹1216

If We factor its FY2025 earnings/valuations, its Price arrives at ₹2204.

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source | NSE Website | Screener.In  | Capital Line | Money Control |Refinitiv |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext  Manage your investments the right way With MProfit. Visit https://www.mprofit.inUse Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D